ODTX Odyssey Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1882782 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets14.2%
Debt / equity0.00x
Current ratio12.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0 | $0 | $0 | $99,000 | $959,000 | $1.92M |
| R&D expense | $42.12M | $36.23M | $32.32M | $26.32M | $30.23M | $38.77M |
| SG&A expense | $11.24M | $10.51M | $7.35M | $10.16M | $13.22M | $7.95M |
| Operating income | -$56.67M | -$55.47M | -$39.78M | -$38.25M | -$41.92M | -$39.16M |
| Interest expense | $12,000 | $20,000 | $10,000 | $1,000 | $2,000 | $2,000 |
| Pretax income | -$53.01M | -$52.80M | -$38.20M | -$35.52M | -$41.20M | -$38.30M |
| Income tax | $49,000 | -$8,000 | $63,000 | -$56,000 | $30,000 | $140,000 |
| Net income | -$53.06M | -$52.79M | -$38.26M | -$35.46M | -$41.23M | -$38.44M |
| EBITDA | -$55.77M | -$54.57M | -$38.61M | -$37.15M | -$40.82M | -$37.86M |
| EPS (basic) | -1.10 | -1.74 | -6.77 | -7.78 | -29.54 | -39.37 |
| EPS (diluted) | -1.10 | -1.74 | -6.77 | -7.78 | -29.54 | -39.37 |
| Weighted avg. shares (diluted) | 48.02M | 30.28M | 5.66M | 4.56M | 1.40M | 976,146 |
| Balance sheet | ||||||
| Cash & equivalents | $80.64M | $82.03M | $35.72M | $49.52M | $163.00M | $54.91M |
| Short-term investments | $245.36M | $228.54M | $140.03M | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 |
| Current assets | $337.80M | $321.46M | $185.10M | — | — | — |
| PP&E, net | $4.63M | $4.88M | $6.56M | — | — | — |
| Goodwill | $14.12M | $14.10M | $14.07M | — | — | — |
| Intangibles | $0 | $86,000 | $160,000 | — | — | — |
| Total assets | $438.10M | $483.85M | $229.07M | — | — | — |
| Current liabilities | $26.10M | $28.30M | $22.21M | — | — | — |
| Total liabilities | $62.33M | $62.63M | $49.21M | — | — | — |
| Shareholders' equity | $375.77M | $421.22M | -$523.69M | -$460.80M | -$436.36M | -$417.17M |
| Shares outstanding | 47.94M | 47.89M | 2.48M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$41.54M | -$34.51M | -$41.03M | -$31.26M | -$34.26M | -$38.62M |
| Capital expenditure | $504,000 | $186,000 | $148,000 | $48,000 | $29,000 | $927,000 |
| Free cash flow | -$42.05M | -$34.69M | -$41.18M | -$31.30M | -$34.29M | -$39.55M |
| Investing cash flow | $43.29M | -$211.44M | $34.80M | -$172.90M | $23.30M | $34.13M |
| Financing cash flow | -$3.18M | $292.16M | $484,000 | $90.78M | $118.72M | $200,000 |
| Depreciation & amortization | $900,000 | $900,000 | $1.17M | $1.10M | $1.10M | $1.30M |
| Stock-based compensation | $7.94M | $5.67M | $2.59M | $4.89M | $3.70M | $2.99M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.